Clinical trial
L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
NCT00125788 · Emmaus Medical, Inc., Industry · Completed
Key facts
| NCT number | NCT00125788 |
|---|---|
| Title | L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia |
| Official title | A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia |
| Lead sponsor | Emmaus Medical, Inc., Industry |
| Collaborators | FDA Office of Orphan Products Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Anemia, Thalassemia |
| Intervention type | Drug |
| Interventions | L-glutamine, Placebo |
| Enrollment | 70 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 2, 2005 |
| Last update posted | Jan 29, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: